| Autor: |
Robb EJ; Pfizer Animal Health, Kalamazoo, MI 49001, USA., Tucker CM, Corley L, Bryson WL, Rogers KC, Sturgess K, Bade DJ, Brodersen B |
| Jazyk: |
angličtina |
| Zdroj: |
Veterinary therapeutics : research in applied veterinary medicine [Vet Ther] 2007 Summer; Vol. 8 (2), pp. 127-35. |
| Abstrakt: |
After undergoing arrival processing at one of two commercial feedlots, feeder calves with clinical signs of bovine respiratory disease (BRD) were randomly assigned to receive either tulathromycin (2.4 mg/kg SC) or enrofloxacin (12.5 mg/kg SC). Additional therapy for calves that did not respond to initial treatment followed a prescribed course. Initial treatment with tulathromycin resulted in significantly higher (P = .009 and P = .031 at sites 1 and 2, respectively) therapeutic success (87.9% and 80%, respectively) than did initial treatment with enrofloxacin (70.2% and 62.5%, respectively). Animals treated with tulathromycin also had fewer subsequent treatments and higher weight gains compared with those treated with enrofloxacin. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
